Zenith Capital Corp. (ZHCLF)
USD 0.0
(-99.9%)
USD 0.0
(-99.9%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 7410.00 USD | 133.68% |
| 2022 | 3171.00 USD | 10.22% |
| 2021 | 2877.00 USD | -13.58% |
| 2020 | 3329.00 USD | -2.23% |
| 2019 | 3405.00 USD | -13.12% |
| 2018 | 3919.00 USD | -0.78% |
| 2017 | 3950.00 USD | -69.76% |
| 2016 | 13.06 Thousand USD | 437.83% |
| 2015 | 2429.00 USD | 24.44% |
| 2014 | 1952.00 USD | -47.7% |
| 2013 | 3732.00 USD | 427.86% |
| 2012 | 707.00 USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 8263.00 USD | 11.51% |
| 2023 Q1 | 3723.00 USD | 17.41% |
| 2023 Q2 | 4516.00 USD | 21.3% |
| 2023 Q4 | 7410.00 USD | -0.9% |
| 2023 Q3 | 7477.00 USD | 65.57% |
| 2022 Q3 | 2464.00 USD | 7.74% |
| 2022 Q4 | 3171.00 USD | 28.69% |
| 2022 FY | 3171.00 USD | 10.22% |
| 2022 Q1 | 2830.00 USD | -1.63% |
| 2022 Q2 | 2287.00 USD | -19.19% |
| 2021 Q3 | 3024.00 USD | 1.1% |
| 2021 Q2 | 2991.00 USD | 0.71% |
| 2021 FY | 2877.00 USD | -13.58% |
| 2021 Q4 | 2877.00 USD | -4.86% |
| 2021 Q1 | 2970.00 USD | -10.78% |
| 2020 Q4 | 3329.00 USD | 2.75% |
| 2020 Q1 | 3466.00 USD | 1.79% |
| 2020 FY | 3329.00 USD | -2.23% |
| 2020 Q2 | 3126.00 USD | -9.81% |
| 2020 Q3 | 3240.00 USD | 3.65% |
| 2019 FY | 3405.00 USD | -13.12% |
| 2019 Q4 | 3405.00 USD | -24.67% |
| 2019 Q3 | 4520.00 USD | 24.14% |
| 2019 Q2 | 3641.00 USD | -49.92% |
| 2019 Q1 | 7271.00 USD | 85.53% |
| 2018 Q2 | 5042.00 USD | 17.36% |
| 2018 Q3 | 3241.00 USD | -35.72% |
| 2018 Q4 | 3919.00 USD | 20.92% |
| 2018 FY | 3919.00 USD | -0.78% |
| 2018 Q1 | 4296.00 USD | 8.76% |
| 2017 Q4 | 3950.00 USD | -31.6% |
| 2017 FY | 3950.00 USD | -69.76% |
| 2017 Q3 | 5775.00 USD | -30.55% |
| 2017 Q2 | 8315.00 USD | -18.11% |
| 2017 Q1 | 10.15 Thousand USD | -22.27% |
| 2016 Q4 | 13.06 Thousand USD | -7.69% |
| 2016 FY | 13.06 Thousand USD | 437.83% |
| 2016 Q1 | 17.81 Thousand USD | 633.39% |
| 2016 Q2 | 15.85 Thousand USD | -11.03% |
| 2016 Q3 | 14.15 Thousand USD | -10.71% |
| 2015 Q2 | 2272.00 USD | -22.46% |
| 2015 Q1 | 2930.00 USD | 50.1% |
| 2015 Q4 | 2429.00 USD | -2.92% |
| 2015 FY | 2429.00 USD | 24.44% |
| 2015 Q3 | 2502.00 USD | 10.12% |
| 2014 Q3 | 2387.00 USD | -9.69% |
| 2014 Q2 | 2643.00 USD | -39.73% |
| 2014 Q1 | 4385.00 USD | 17.5% |
| 2014 Q4 | 1952.00 USD | -18.22% |
| 2014 FY | 1952.00 USD | -47.7% |
| 2013 Q4 | 3732.00 USD | -5.69% |
| 2013 FY | 3732.00 USD | 427.86% |
| 2013 Q3 | 3957.00 USD | -23.27% |
| 2013 Q2 | 5157.00 USD | -43.57% |
| 2013 Q1 | 9139.00 USD | 1192.64% |
| 2012 FY | 707.00 USD | 0.0% |
| 2012 Q4 | 707.00 USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -220.779% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 99.622% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 99.93% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 98.658% |
| Rebus Holdings, Inc. | 5000.00 USD | -48.2% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.994% |
| Qrons Inc. | 420.00 USD | -1664.286% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 99.038% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 99.973% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 98.458% |
| Skye Bioscience, Inc. | 11.94 Million USD | 99.938% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 99.981% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 99.897% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | 90.295% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.993% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 99.483% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | 89.76% |
| Mesoblast Limited | 667.9 Million USD | 99.999% |
| Marizyme, Inc. | 22.01 Million USD | 99.966% |
| Genus plc | 1.02 Billion USD | 99.999% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 99.454% |
| Pharming Group N.V. | 462.85 Million USD | 99.998% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 99.776% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 98.515% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 98.818% |
| ContraFect Corporation | 20.67 Million USD | 99.964% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | 98.102% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | 98.061% |
| IMV Inc. | 31.33 Million USD | 99.976% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 99.821% |
| MultiCell Technologies, Inc. | 126.22 USD | -5770.702% |
| ONE Bio Corp. | 70.08 Million USD | 99.989% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 99.211% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.994% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | 98.284% |
| Q BioMed Inc. | 3.51 Million USD | 99.789% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 99.979% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | 97.164% |
| Biomind Labs Inc. | 73.81 Thousand USD | 89.962% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.998% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 99.489% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 99.975% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 99.73% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 98.922% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 99.715% |
| GB Sciences, Inc. | 103.44 Thousand USD | 92.837% |
| Alpha Cognition Inc. | 2.45 Million USD | 99.698% |
| HST Global, Inc. | 1526.00 USD | -385.583% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 99.25% |
| Halberd Corporation | 10.13 Thousand USD | 26.858% |
| Enzolytics Inc. | 361.7 Million USD | 99.998% |
| Agentix Corp. | 261.39 Thousand USD | 97.165% |
| Resverlogix Corp. | 8.11 Million USD | 99.909% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 99.605% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 99.984% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 98.842% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | 67.473% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 99.917% |
| AVAX Technologies, Inc. | 7.37 Million USD | 99.9% |
| Genscript Biotech Corporation | 3.38 Billion USD | 100.0% |
| Ember Therapeutics, Inc. | 184.00 USD | -3927.174% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | 97.697% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | 97.165% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 99.201% |
| Kadimastem Ltd | 2.3 Million USD | 99.678% |
| Helix BioMedix, Inc. | 3.02 Million USD | 99.755% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.986% |
| BioStem Technologies, Inc. | 14.56 Million USD | 99.949% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | 87.021% |
| LadRx Corporation | 2.3 Million USD | 99.679% |
| Cell Source, Inc. | 195.17 Thousand USD | 96.203% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 97.905% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 97.905% |
| NovAccess Global Inc. | 62.24 Thousand USD | 88.096% |
| Affymax, Inc. | 7.44 Million USD | 99.9% |
| Itoco Inc. | 1.4 Million USD | 99.471% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | 92.254% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | 93.009% |
| Mobile Lads Corp. | 52.00 USD | -14150.0% |
| CytoDyn Inc. | 11.13 Million USD | 99.933% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | 94.817% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | 58.557% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | 98.078% |
| SYBLEU INC | 330.46 Thousand USD | 97.758% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | 98.19% |
| International Stem Cell Corporation | 5.39 Million USD | 99.863% |
| Bioxytran, Inc. | 137.63 Thousand USD | 94.616% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 99.951% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 99.955% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | 90.62% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 99.143% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 99.901% |
| Neutra Corp. | 2851.00 USD | -159.909% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 99.977% |
| PureTech Health plc | 693.97 Million USD | 99.999% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 99.908% |
| IXICO plc | 15.84 Million USD | 99.953% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 99.911% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.993% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Cellectis S.A. | 333.99 Million USD | 99.998% |